• BPL Supports the Immune Deficiency Foundation Research Grant Program for Second Year in a Row
  November 02, 2022
• 10/10 Marks A Day to Bring Awareness to One of The Rarest Bleeding Disorders
  October 10, 2022
• The X Factor: Elevating the Voices of Rare Disease Patients Has Never Been More Vital
  October 10, 2022
• BPL Recognized as ‘Fast 50 Company’ for the Third Year Running
  September 26, 2022
• Permira Funds and the Marcucci Family Complete Investment in Kedrion and BPL and Announce Appointment of Ugo Di Francesco as CEO
  September 01, 2022
• Hereditary Factor X Deficiency (HFXD) Survey Shows Unmet Need in Patients With Rare Bleeding Disorder
  August 16, 2022
• BPL USA Awarded as a “Best Place to Work”
  July 26, 2022
• BPL Celebrates World Blood Donor Day
  June 14, 2022
• BPL Expands Options for Patients in the Dominican Republic With Marketing Authorization for Coagadex^®
  May 31, 2022
• BPL Receives Orphan Drug Marketing Authorization for Coagadex® in Mexico
  May 04, 2022
• BPL Marks Bleeding Disorders Awareness Month 2022
  March 31, 2022
• BPL Granted a New Patent in the US
  March 30, 2022
• BPL Supports Rare Disease Day 2022
  February 28, 2022
• BPL Full Year 2021 Results: BPL Delivers Another Strong Performance
  February 07, 2022
• BPL Affiliate Makes First Ever Sale to Mexico
  February 04, 2022
• BPL Granted Licence From the National Medical Products Administration (NMPA) to Market ALBUMINEX^® 25% Product to China
  January 24, 2022
• Permira Acquires Kedrion and BPL
  January 20, 2022
• BPL to Support the Immune Deficiency Foundation Research Grant Program
  October 12, 2021
• Second Annual Hereditary Factor 10 Deficiency Awareness Day Kicks Off October 10
  October 08, 2021
• BPL Announces the Kick-off of the Hereditary Factor X Deficiency in America Survey
  September 28, 2021
• BPL Recognized as 'Fast 50 Company' for the Second Year Running
  September 20, 2021
• BPL Delivers a Strong Performance in Its 1st Half 2021 Results
  July 23, 2021
• EU Health Commissioner Says Plasma Donation Plays a Vital Role
  June 14, 2021
• Bio Products Laboratory Support for Strong Trade Links with India
  May 04, 2021
• BPL and Atlantic Research Group Enter Into Long-Term Collaboration
  April 28, 2021
• Bio Products Laboratory: £23m Investment in New 1,000 Square Meter Filling and Sterilisation Facility at Elstree
  March 29, 2021
• BPL Sells 25 US Plasma Centres to Grifols for $370 million
  March 01, 2021
• Bio Products Laboratory Receives Triangle Business Journal’s Fast 50 Award
  October 19, 2020
• BPL Announces October 10th Hereditary Factor X Deficiency Awareness Day
  October 08, 2020
• Bio Products Laboratory USA Recognized as Triangle Business Journal’s Best Places to Work
  September 14, 2020
• Fourth Update on BPL’s Continued Efforts During the COVID-19 Pandemic
  June 05, 2020
• Bio Products Laboratory Announces Launch of ALBUMINEX^® 5% and ALBUMINEX^® 25% With Supply Immediately Available in the United States
  May 27, 2020
• Third Update on BPL’s Work to Ensure the Provision of Critical Medicines in Response to the COVID-19 Pandemic
  May 06, 2020
• Further Update on BPL’s Actions to Ensure the Provision of Critical Medicines in Response to the Worldwide COVID-19 Pandemic
  April 07, 2020
• Global Plasma Leaders Collaborate to Accelerate Development of Potential Covid-19 Hyperimmune Therapy
  April 06, 2020
• COVID-19 and Update on Actions Taken to Ensure Patient Needs Will Continue to be Met
  March 18, 2020
• FDA Approves Bio Products Laboratory’s Gammaplex® 10% for Treatment of Primary immunodeficiency and Chronic Immune Thrombocytopenic Purpura
  February 07, 2017
• Bio Products Laboratory Receives European Approval for Coagadex® (Human Coagulation Factor X)
  March 30, 2016
• Bio Products Laboratory Announces Supply of COAGADEX® Now Available in the United States
  December 03, 2015
• Press Release: Bio Products Laboratory Receives FDA approval for Coagadex® (Coagulation Factor X, Human) First-ever FDA-approved treatment for hereditary factor X deficiency
  October 21, 2015
• Press Release: Gammaplex® Approved For Use In Pediatric Patients
  October 21, 2015
• Press Release: FDA Accepts BPL’s Amended BLA Submission for Coagadex® (Coagulation Factor X, Human)
  May 27, 2015
• Press Release: Bio Products Laboratory, Ltd. Announces Results from Phase III Registration Study of its Factor X Coagulation Product
  April 17, 2015
• Bio Products Laboratory Inc. (BPL) Announces NEW Vial Size of Gammaplex® for the Treatment of Primary Immunodeficiency and Chronic Immune Thrombocytopenic Purpura
  June 16, 2014
• Press Release: Change of name to BPL Holdings for Plasma Resources UK
  January 01, 2014
• Press Release: BPL Announces Strong Progress on the World’s First Licensed Factor X Product
  December 31, 2013
• Press Release: Change of Ownership
  September 01, 2013
• Parliamentary Year Book
  January 28, 2013
• Press Release on Investment Request
  September 01, 2012
• Approval Letter - Gammaplex
  September 17, 2009